tetano
Editor, Senior Moderator
Br J Haematol
. 2020 Jun 1.
doi: 10.1111/bjh.16901. Online ahead of print.
Interleukin-6 Blockade Treatment for COVID-19 Associated Cytokine Release Syndrome in a Patient With Poorly Controlled Chronic Myeloid Leukaemia
Amita Ranger[SUP] 1 [/SUP], Ruby Haji, Richard Kaczmarski[SUP] 2 [/SUP], Akila Danga[SUP] 1 [/SUP]
Affiliations
Abstract
In December 2019, a novel coronavirus pneumonia, coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China. A hyperinflammatory immune response, or cytokine release syndrome (CRS) is observed in critically unwell patients with SARS-CoV-2 globally. Severe lymphopenia, hyperactivated pro-inflammatory T cells[SUP]1[/SUP] and decreased regulatory T cells[SUP]2[/SUP] are seen in these critically ill patients, suggesting dysregulated immune responses.
. 2020 Jun 1.
doi: 10.1111/bjh.16901. Online ahead of print.
Interleukin-6 Blockade Treatment for COVID-19 Associated Cytokine Release Syndrome in a Patient With Poorly Controlled Chronic Myeloid Leukaemia
Amita Ranger[SUP] 1 [/SUP], Ruby Haji, Richard Kaczmarski[SUP] 2 [/SUP], Akila Danga[SUP] 1 [/SUP]
Affiliations
- PMID: 32480422
- DOI: 10.1111/bjh.16901
Abstract
In December 2019, a novel coronavirus pneumonia, coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China. A hyperinflammatory immune response, or cytokine release syndrome (CRS) is observed in critically unwell patients with SARS-CoV-2 globally. Severe lymphopenia, hyperactivated pro-inflammatory T cells[SUP]1[/SUP] and decreased regulatory T cells[SUP]2[/SUP] are seen in these critically ill patients, suggesting dysregulated immune responses.